Previous Close | 25.15 |
1-Year Change | 30.65% |
6-Months Change | -1.1% |
3-Months Change | -8.74% |
Moving Avg (50d) | 25.133 |
Moving Avg (200d) | 25.355 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 368.1M |
Beta (3-Years) | 0.74 |
Revenue Growth (ttm) | 7.14% |
Net Profit Margin (ttm) | -15.05% |
Return On Assets (ttm) | -7.49% |
EPS (ttm) | -1.69 |
PE Ratio (ttm) | -14.88 |
Dividend Yield | % |
Asset Description: | Anika Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-10-10 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
24.647 | 23.892 | 23.389 | 22.635 | 21.377 | 20.12 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |